Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Prescription drug coverage policies: evaluating impacts on patient access, outcomes, and health system expenditures
FY 2013-14
Summary
Prescription drugs are among the most important modern medical treatments, comprising a significant and growing segment of global health spending. Evaluating models for providing prescription drug insurance is crucial for informing evidence-based pharmaceutical policy that achieves the goal of promoting access to quality medicines at a cost affordable to patients, governments, and the private sector. My doctoral research will evaluate two drug insurance changes resulting from the implementation of the Patient Protection and Affordable Care Act in the United States (US) which are likely to make a significant impact on patients and the health system: the rise in high deductible (catastrophic) health plans and the provision of oral contraceptives at no cost to women.
High deductible drug plans require a significant amount of patient spending before coverage kicks in. This design may impact levels of out-of-pocket costs, medicine use, adherence, and health outcomes. Evidence on the effects of these plans is needed given the potential implications for health system costs and patient health and the fact that catastrophic insurance models have rapidly become popular in the US and are now the predominant model for public drug benefits in Canada.
Providing women with access to affordable birth control is important for women's health and autonomy. Given that in most developed countries women are required to pay at least a small portion of the cost of contraception, an evaluation of the impact of providing oral contraceptives at no cost to the patient would provide valuable policy lessons for governments around the globe.
In summary, an examination of these drug coverage policies will provide timely and useful feedback to policymakers in the US, Canada, and elsewhere. Provincial governments, in particular, may extract lessons as they continue to consider changes to public drug plans that comprise an increasing portion of provincial health care budgets.
Department
Program
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
307701
Name
Daw Jamie R
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
Prescription drug coverage policies: evaluating impacts on patient access, outcomes, and health system expenditures
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Access To Medicines; Cost Related Non-Adherence; Health Outcomes; Health System Costs; Patient Cost Burden; Pharmaceutical Policy; Prescription Drug Coverage; Reproductive Health
Abstract
Prescription drugs are among the most important modern medical treatments, comprising a significant and growing segment of global health spending. Evaluating models for providing prescription drug insurance is crucial for informing evidence-based pharmaceutical policy that achieves the goal of promoting access to quality medicines at a cost affordable to patients, governments, and the private sector. My doctoral research will evaluate two drug insurance changes resulting from the implementation of the Patient Protection and Affordable Care Act in the United States (US) which are likely to make a significant impact on patients and the health system: the rise in high deductible (catastrophic) health plans and the provision of oral contraceptives at no cost to women.
High deductible drug plans require a significant amount of patient spending before coverage kicks in. This design may impact levels of out-of-pocket costs, medicine use, adherence, and health outcomes. Evidence on the effects of these plans is needed given the potential implications for health system costs and patient health and the fact that catastrophic insurance models have rapidly become popular in the US and are now the predominant model for public drug benefits in Canada.
Providing women with access to affordable birth control is important for women's health and autonomy. Given that in most developed countries women are required to pay at least a small portion of the cost of contraception, an evaluation of the impact of providing oral contraceptives at no cost to the patient would provide valuable policy lessons for governments around the globe.
In summary, an examination of these drug coverage policies will provide timely and useful feedback to policymakers in the US, Canada, and elsewhere. Provincial governments, in particular, may extract lessons as they continue to consider changes to public drug plans that comprise an increasing portion of provincial health care budgets.
Competitiondate
201310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Daw, Jamie R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~